Abstract

Due to the advancement of genome sequencing techniques, a great stride has been made in exome sequencing such that the association study between disease and genetic variants has become feasible. Some powerful and well-known association tests have been proposed to test the association between a group of genes and the disease of interest. However, some challenges still remain, in particular, many factors can affect the performance of testing power, e.g., the sample size, the number of causal and non-causal variants, and direction of the effect of causal variants. Recently, a powerful test, called TREM , is derived based on a random effects model. TREM has the advantages of being less sensitive to the inclusion of non-causal rare variants or low effect common variants or the presence of missing genotypes. However, the testing power of TREM can be low when a portion of causal variants has effects in opposite directions. To improve the drawback of TREM , we propose a novel test, called TROB , which keeps the advantages of TREM and is more robust than TREM in terms of having adequate power in the case of variants with opposite directions of effect. Simulation results show that TROB has a stable type I error rate and outperforms TREM when the proportion of risk variants decreases to a certain level and its advantage over TREM increases as the proportion decreases. Furthermore, TROB outperforms several other competing tests in most scenarios. The proposed methodology is illustrated using the Shanghai Breast Cancer Study.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call